High-yield points
- What it is: choroidal arteries drain into a persistent median prosencephalic vein, which is not a true vein of Galen. Drainage is often through a falcine sinus, with an absent straight sinus .
- Age shapes presentation: neonates with heart failure, infants with hydrocephalus and macrocephaly .
- Hydrocephalus is from venous hypertension: embolize first, and shunt only if needed .
- Treatment: staged transarterial embolization, timed by the Bicêtre score. About 62–68% have good outcomes and 10–14% die .
- Neonates and heart failure do worst (48% good outcome vs 77% in infants) .
- Fetal falcine sinus 7 mm or wider = high risk. In utero embolization is emerging but raises preterm delivery .
- Genetics: RASA1 and EPHB4 .
Landmark papers
- Bicêtre experience (Lasjaunias et al., Neurosurgery 2006): 216 treated patients. 10.6% died, and 74% of survivors were neurologically normal .
- In utero embolization (Orbach et al., JAMA 2025): a falcine sinus 7 mm or wider identifies high-risk fetuses. Of 7 fetuses enrolled, 5 were embolized; 3 embolized children survived, all without developmental delay (overall mortality 43%), but 5 of 7 (71.4%) had unscheduled deliveries .
The vein of Galen malformation (VOGM, or vein of Galen aneurysmal malformation) is the most common congenital cerebrovascular anomaly . Choroidal arteries drain directly into a persistent, dilated median prosencephalic vein (the embryonic forerunner of the vein of Galen). This differs from a parenchymal AVM that drains into an already formed, dilated vein of Galen . The very high flow causes neonatal heart failure and venous hypertension, and it injures the developing brain.
Anatomy and genetics
- Types:
- Choroidal: many feeders into the venous pouch.
- Mural: few feeders into the wall of the pouch.
- Mixed.
- In one series, mixed (31.7%), mural (29.3%) and choroidal (26.8%) types were all common, and choroidal and posterior cerebral arteries were the usual feeders .
- Genetics:
- Exome study (310 families): loss-of-function de novo RASA1 variants were strongly enriched, and transmitted EPHB4 variants were enriched. Variants also occurred in ACVRL1, NOTCH1, ITGB1 and PTPN11 .
- VOGM is an occasional feature of capillary malformation–arteriovenous malformation syndrome (RASA1) and hereditary hemorrhagic telangiectasia .
Presentation by age
- Fetus: detected in the third trimester.
- In a meta-analysis of 226 fetuses, ventriculomegaly occurred in 31.8%, cardiac compromise in 23.1% and hydrops in 7.3%.
- Neonatal death occurred in 23.8%, and only 29.7% were free of neurological impairment .
- Neonate: high-output heart failure, often refractory, and pulmonary hypertension.
- Severe neonatal cardiac failure and pulmonary hypertension at or above systemic pressure predicted death .
- Untreated symptomatic neonates have almost 100% morbidity and mortality .
- Infant: macrocephaly and hydrocephalus, prominent scalp veins and developmental delay.
- In one cohort, 65.9% presented with hydrocephalus and 61.0% with heart failure .
- Hydrocephalus mechanism:
- It develops in about half of patients. Venous hypertension impairs CSF absorption.
- Treat it by embolization to correct the "hydrodynamic disorder." Avoid shunting unless hydrocephalus stays symptomatic after embolization .
Evaluation and selection
- Bicêtre neonatal evaluation score: a multi-organ score used to decide whether and when to treat a neonate. Treatment guided by it gave better neurological outcomes in a meta-analysis .
- Children with low scores have still done well after embolization, so the decision should rest with an experienced multidisciplinary team .
- Brain injury at presentation: children with severe diffuse brain injury (encephalomalacia) are often not offered treatment .
- Fetal risk marker: a falcine sinus 7 mm or wider identifies high-risk fetuses. A mean width of 10.3 mm corresponded to 90% expected mortality with standard postnatal care .
Treatment
- Staged transarterial embolization is the treatment of choice. The goal is normal development rather than a normal-looking angiogram .
- Bicêtre experience (216 treated):
- 10.6% died.
- 74% of survivors were neurologically normal, 15.6% moderately delayed and 10.4% severely delayed .
- Timing: within an "optimal therapeutic window." Embolize urgently for refractory neonatal heart failure, otherwise electively later in infancy .
- Neonates with refractory heart failure (9 treated): heart failure was controlled in 8, and 66.7% had normal development .
- Meta-analyses:
- 578 patients:
- Mortality 14%, good neurological outcome 62% and poor outcome 21%.
- Neonates did worse than infants (48% vs 77% good outcome), and heart failure lowered the odds of a good outcome (OR 0.50) .
- 667 patients:
- Complete occlusion 57%, good outcome 68%.
- Post-embolization mortality 10% and complications 37% (hemorrhage, ischemia, hydrocephalus, leg ischemia, vessel perforation) .
- Avoiding complications (33 children, 91 sessions):
- 30.3% had major periprocedural neurological complications, and half of those died.
- Predictors: internal cerebral veins draining into the venous pouch, and microcatheters larger than 2.0F.
- Lessons: check internal cerebral vein drainage on MR venography beforehand, avoid over-embolizing the pouch, treat distal fistulae before proximal ones, and use small catheters in neonates .
- In utero embolization (investigational):
- Transuterine, ultrasound-guided coiling of the venous pouch in high-risk fetuses: 5 of 7 were successfully embolized, with a 33.4% drop in cardiac output.
- 3 of the 5 embolized children survived, all without developmental delay (overall mortality 43%); 5 of 7 (71.4%) had unscheduled deliveries, and 3 were preterm .
Long-term outcome
- Outcomes worsen with longer follow-up:
- Of 52 children assessed at school age, 19 had died. Of 33 survivors, 19 had good outcomes and 14 poor.
- Even "good outcome" children often had neuropsychological problems needing support .
- Predictors of a poor outcome: younger age at diagnosis, heart failure and seizures. In one cohort, 50% had normal or mildly disabled function and survival was 78% .
Related topics
- Brain AVMs in Children: parenchymal arteriovenous malformations.
- Dural Arteriovenous Fistulas in Children: other high-flow pediatric shunts with heart failure.
- Hereditary Vasculopathies: HHT and RASA1-related syndromes.
- Benign vs Malignant Macrocephaly: macrocephaly in infants.
- Ventriculomegaly vs Hydrocephalus: fetal ventriculomegaly.
References
- Orbach DB, Shamshirsaz AA, Wilkins-Haug L, et al. In utero embolization for fetal vein of Galen malformation. JAMA 2025;334(10):878–885. doi:10.1001/jama.2025.12363. PMID 40788723. verified
- Lasjaunias PL, Chng SM, Sachet M, et al. The management of vein of Galen aneurysmal malformations. Neurosurgery 2006;59(5 Suppl 3):S184–S194. doi:10.1227/01.NEU.0000237445.39514.16. PMID 17053602. verified
- Chow ML, Cooke DL, Fullerton HJ, et al. Radiological and clinical features of vein of Galen malformations. J Neurointerv Surg 2015;7(6):443–448. doi:10.1136/neurintsurg-2013-011005. PMID 24789593. verified
- Zhao S, Mekbib KY, van der Ent MA, et al. Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations. Nat Commun 2023;14(1):7452. doi:10.1038/s41467-023-43062-z. PMID 37978175. verified
- Duran D, Karschnia P, Gaillard JR, et al. Human genetics and molecular mechanisms of vein of Galen malformation. J Neurosurg Pediatr 2018;21(4):367–374. doi:10.3171/2017.9.PEDS17365. PMID 29350590. verified
- D'Amico A, Tinari S, D'Antonio F, et al. Outcome of fetal vein of Galen aneurysmal malformations: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2022;35(25):5312–5317. doi:10.1080/14767058.2021.1878494. PMID 33508985. verified
- Taffin H, Maurey H, Ozanne A, et al. Long-term outcome of vein of Galen malformation. Dev Med Child Neurol 2020;62(6):729–734. doi:10.1111/dmcn.14392. PMID 31713850. verified
- Berenstein A, Fifi JT, Niimi Y, et al. Vein of Galen malformations in neonates: new management paradigms for improving outcomes. Neurosurgery 2012;70(5):1207–1213. doi:10.1227/NEU.0b013e3182417be3. PMID 22089754. verified
- Paramasivam S. Hydrocephalus in vein of Galen malformations. Neurol India 2021;69(Supplement):S376–S379. doi:10.4103/0028-3886.332279. PMID 35102992. verified
- Brinjikji W, Krings T, Murad MH, et al. Endovascular treatment of vein of Galen malformations: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2017;38(12):2308–2314. doi:10.3174/ajnr.A5403. PMID 28982789. verified
- McSweeney N, Brew S, Bhate S, et al. Management and outcome of vein of Galen malformation. Arch Dis Child 2010;95(11):903–909. doi:10.1136/adc.2009.177584. PMID 20605862. verified
- Yan J, Wen J, Gopaul R, et al. Outcome and complications of endovascular embolization for vein of Galen malformations: a systematic review and meta-analysis. J Neurosurg 2015;123(4):872–890. doi:10.3171/2014.12.JNS141249. PMID 26230476. verified
- Bhatia K, Mendes Pereira V, Krings T, et al. Factors contributing to major neurological complications from vein of Galen malformation embolization. JAMA Neurol 2020;77(8):992–999. doi:10.1001/jamaneurol.2020.0825. PMID 32338714. verified
Verification (2026-11-03): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every figure cited was checked against the PubMed abstract. Full texts were not reviewed. The Bicêtre score's individual components and cutoffs are not in the abstracts reviewed, so they are not given. The choroidal/mural type descriptions (many vs few feeders), the clinical signs listed for infants and the "elective embolization later in infancy" timing are standard teaching consistent with references 2 and 3. Reference 12's pooled sample includes a small proportion of children and adults (12%). The schematic is an original figure.